News Release Back
9 Meters Biopharma, Inc. Highlighted at Upcoming Truist Securities' Catalyst Conference Call Series: "Prepping Ahead of Data"
Conference Call Scheduled for
Prepping ahead of Data Conference Call Series
Topic: Preliminary Ph1/2 data from short bowel syndrome expected in 2H2020
Speakers: President & CEO,
Conference Details: To register for NMTR call, please use: THIS LINK
An audio replay of the call will be accessible via THIS LINK, until
For more information, please visit www.9meters.com or follow 9 Meters on Twitter and LinkedIn.
This press release includes forward-looking statements based upon the Company's current expectations. Forward-looking statements involve risks and uncertainties, and include, but are not limited to, the potential effects of the ongoing coronavirus outbreak and related mitigation efforts on the Company's clinical, financial and operational activities; the Company's continued listing on Nasdaq; expectations regarding future financings; the future operations of the Company; the nature, strategy and focus of the Company; the development and commercial potential and potential benefits of any product candidates of the Company; anticipated preclinical and clinical drug development activities and related timelines, including the expected timing for data and other clinical and preclinical results; the Company having sufficient resources to advance its pipeline; and any other statements that are not historical fact. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: (i) uncertainties associated with the clinical development and regulatory approval of product candidates; (ii) risks related to the inability of the Company to obtain sufficient additional capital to continue to advance these product candidates and its preclinical programs; (iii) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (iv) risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; (v) the impact of COVID-19 on our operations, clinical trials or proposed merger and future financings and (vi) risks associated with the possible failure to realize certain anticipated benefits of the Company's recent merger and the
Email Alerts Print Page
Data may be delayed up to 15 minutes